Cathy Slaughter
Adult Health · Taylor, MINPI 1457723280
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$546
- Pfizer$496
- GSK$496
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$388
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,940100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $1,264 |
| AbbVie | 67 | $1,072 |
| Novo Nordisk | 33 | $546 |
| Pfizer | 26 | $496 |
| GSK | 37 | $496 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $388 |
| Lilly USA, LLC | 17 | $277 |
| Exact Sciences | 13 | $272 |
| Eisai Inc. | 9 | $147 |
| Xeris Pharmaceuticals, Inc. | 4 | $99 |
| UCB, Inc. | 5 | $81 |
| Amarin Pharma, Inc. | 5 | $73 |
| Merck | 4 | $71 |
| Novartis | 4 | $71 |
| Amgen | 3 | $64 |
| Nestle Healthcare Nutrition Inc. | 4 | $58 |
| Johnson & Johnson | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Dexcom, Inc. | 3 | $41 |
| Lundbeck LLC | 2 | $37 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Bausch Health US, LLC | 2 | $29 |
| Tolmar, Inc. | 1 | $27 |
| Antares Pharma, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Evoke Pharma, Inc. | 1 | $13 |
How this compares
$5,940 in reported general payments places this provider in the 90th percentile of 527 adult health providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $56,189 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $36,821 |
| EliquisApixaban | 28 | $23,486 |
| JanuviaSitagliptin Phosphate | 17 | $16,546 |
| TrulicityDulaglutide | 16 | $13,895 |
| LinzessLinaclotide | 11 | $10,841 |
| XareltoRivaroxaban | 13 | $6,903 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 163 | $5,348 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $4,636 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 354 | $3,835 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,539 |
| Varenicline Tartrate | 13 | $3,328 |
| Ventolin HfaAlbuterol Sulfate | 49 | $2,670 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 175 | $2,144 |
| Gabapentin | 162 | $1,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $546 | $56,18948 claims |
| GSKTrelegy Ellipta | $496 | $36,82155 claims |
| PfizerEliquis | $496 | $23,48628 claims |
| MerckJanuvia | $71 | $16,54617 claims |
| Lilly USA, LLCTrulicity | $277 | $13,89516 claims |
| AbbVieLinzess | $1,072 | $10,84111 claims |
| Johnson & JohnsonXarelto | $46 | $6,90313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 adult health providers in Michigan.
Other adult health in Taylor
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
- Mary KaiserKalamazoo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.